A pilot study for the treatment of non-Hodgkin's lymphoma in children with acquired immunodeficiency syndromes

International Journal of Pediatric Hematology/Oncology

Volumn 7, Issue 3, 2001, Pages 167-187

  Gonzalez, C E ^a   Shad, A ^a   Adde, M ^a   Mueller, B U ^a   Venzon, D J ^a   Avila, N ^a   Jaffe, E S ^a   Kingma, D ^a   Wood, L V ^a   Pizzo, P A ^a   Smithson, W A ^a   Sleasman, J W ^a   Magrath, I ^a  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Immunodeficiency; NHL; Non Hodgkin's lymphoma

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DIDANOSINE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IMMUNOGLOBULIN; LAMIVUDINE; MESNA; METHOTREXATE; ONDANSETRON; PENTAMIDINE; PREDNISONE; PROTEINASE INHIBITOR; RETINOIC ACID; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; AEROSOL; ARTICLE; BACTEREMIA; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CAUSE OF DEATH; CHILD; CLINICAL ARTICLE; COLITIS; COMORBIDITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HEMATOLOGIC DISEASE; HERPES VIRUS INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; LIVER TOXICITY; MALE; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; ORBIT CELLULITIS; PILOT STUDY; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; THRUSH;

EID: 0034819459     PISSN: 10702903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Immunodeficiency in humans as a risk factor in the development of malignancy
2. Cancer in children with primary or secondary immunodeficiencies
3. Human Immunodeficiency virus-associated lymphomas
4. Risk of cancer in renal-transplant recipients
5. De novo malignancy in pediatric organ transplant recipients
6. Centers for Disease Control and Prevention: HIV/AIDS surveillance report
7. Cancer in human immunodeficiency virus-infected children: A case series from the Children's Cancer Group and the National Cancer Institute
8. Malignant Non-Hodgkin's lymphomas in children
9. Malignancies in children with human immunodeficiency virus type 1 infection
10. Malignancies in UK children with HIV-infection acquired from mother to child transmission
11. Clinical evaluation of 451 patients with HIV related Non-Hodgkin's lymphoma: Experience of the talian cooperative group on AIDS and tumors (GICAT)
12. Treatment outcome in children with malignancies associated with human immunodeficiency virus infection
13. Primary central nervous system lymphoma in a pediatric patient with acquired immune deficiency syndrome. Treatment with radiation therapy
14. Low dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection
15. AIDS associated non-Hodgkin's lymphoma in San Francisco
16. AIDS-related lymphoid neoplasia: The Memorial Hospital experience
17. Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS): The New York University medical Center experience with 105 patients (1981-1986)
18. Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy
19. AIDS related malignant lymphoma: Results of prospective treatment trials
20. Centers for Disease Control and Prevention: 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age
21. 1993 Revised classification system for human HIV-infection and expanded surveillance case definition for AIDS among adolescents and adults
22. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long term mortality risk in HIV-1-infected children
23. Serum HIV-1 p24 antibody, HIV-1 RNA copy number and CD4 lymphocyte percentage are independently associated with risk of mortality in HIV-1-infected children
24. Epstein-Barr virus is infrequently identified in non-Hodgkin's lymphomas associated with Ho gkin's disease
25. Primary anaplastic large cell (KI-1 positive) lymphoma of the mandible as the initial manifestation of acquired immunodeficiency syndrome in a pediatric patient
26. Long term remissions following one and two dose chemotherapy for African lymphoma
27. American Burkitt's lymphoma - A clinicopathological study of 30 cases. Clinical factors relating to long term survival
28. Dose rate: An important prognostic determinant in non-Hodgkin's lymphomas in young patients
29. Non Hodgkin's lymphoma in children
30. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma results of a tree-structures survival analysis
31. The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma
32. A 10-year update of CHOP-Bleo in the treatment of diffuse large-cell lymphoma
33. Curability of Burkitt's lymphoma with high-dose cyclophosphamide high-dose methotrexate therapy and intrathecal chemoprophylaxis
34. Disease patterns and survival after acquired immunodeficiency syndrome diagnosis in human immunodeficiency virus-infected children
35. Survival in children with perinatally acquired human immunodeficiency virus type 1 infection
36. AIDS-associated non-Hodgkin's lymphoma
37. Human immunodeficiency virus-related lymphoma
38. Cancers complicating organ transplantation
39. Malignant tumors in renal transplant recipients receiving cyclosporine: A survey of 598 first-kidney transplantations
40. Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma
41. Phase I/II trial of filgrastim (r-metHug-CSF), CEOP chemotherapy and ART in HIV-related non-Hodgkin's lymphoma
42. Addition of granulocyte colony-stimulating factor to chemotherapy in patients with AIDS-related lymphoma: Effects on neutrophil FCγ receptor expression and soluble FCγ RIII levels
43. Impairment of neutrophil bactericidal capacity in patients with AIDS
44. Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection
45. Chemotherapy combined with zidovudine and GM-CSF in human immunodeficiency virus-related non-Hodgkin's lymphoma
46. Low dose methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone with zalcitabine in patients with acquired immunodeficiency syndrome-related lymphoma: Effect on human interleukin-6 over time
47. Combination chemotherapy, adriamycin, bleomycin, vincristine (ABV) with dideoxyinosine (DDI) or dideoxycytidine (DDC) in advanced AIDS-related Kaposi's sarcoma (ACTG 163)
48. Declining morbility and mortality among patients with advanced human immunodeficiency virus infection
49. Age, thymopoiesis, and CD4+T-lymphocyte regeneration after intensive chemotherapy
50. Chemotherapy for AIDS-related malignancies does not increase HIV viraemia
51. HIV viral burden during EPOCH chemotherapy for HIV-related lymphomas
52. Viral load changes in patients undergoing chemotherapy for AIDS-KS
53. Variability in repeated consecutive measurements of plasma human immunodeficiency virus RNA in persons receiving stable nucleoside reverse transcriptase inhibitor therapy or no treatment
54. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
55. Switching viral latency to viral lysis: A novel therapeutic approach for Epstein-Barr virus-associated neoplasia
56. Use of Epstein-Barr virus nuclear antigen-1 in targeted therapy of EBV-associated neoplasia